CDTTW — CDT Equity Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1896212 ·
Last close
$0.01
Market Cap
—
52W High
$0.01
52W Low
$0.01
ADV30
10,839
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,002,000 | -4,641,000 | 126,708,000 | 747,000 | 23,615,000 |
| Mar 2026 | 0 | — | -3,656,000 | -4,063,000 | 127,087,000 | 97,000 | 21,636,000 |
| Dec 2025 | 0 | — | -21,156,000 | -21,325,000 | 5,650,000 | 1,509,000 | 12,820,000 |
| Sep 2025 | 0 | — | -6,936,000 | -7,118,000 | 8,552,000 | 3,838,000 | 4,274,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-13,520,000
Investing CF
$-404,000
Financing CF
$11,982,000
CapEx
$-2,403,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
—
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-72,388,000
Inventory
—
Receivables
$146,000
ST Investments
—
EBIT TTM
$-38,341,000
Pretax Income TTM
$-38,533,000
Interest Exp TTM
$192,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -36,660,000 | -39,224,000 | 5,650,000 | 12,820,000 | -7,170,000 | -15,555,000 |
| Dec 2024 | 0 | -15,105,000 | -17,802,000 | 4,193,000 | 10,986,000 | -6,793,000 | -9,682,000 |
| Dec 2023 | 0 | -5,262,000 | -535,000 | 7,224,000 | 7,681,000 | -457,000 | -7,725,000 |
| Dec 2022 | 0 | -3,160,000 | -4,887,000 | 5,000 | 10,094,000 | -10,089,000 | -2,266,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.06T | $1184.78 | — |
| JNJ | JOHNSON & JOHNSON | $655.37B | $271.95 | — |
| ABBV | AbbVie Inc. | $470.55B | $266.28 | — |
| MRK | Merck & Co., Inc. | $366.84B | $148.69 | — |
| NVS | NOVARTIS AG | $279.18B | $146.88 | — |
News headlines (Yahoo Finance, 1h cache)
CDT Equity Inc. Announces Reverse Stock Split
2026-07-16 12:00 · Yahoo
CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven Discovery
2026-04-16 12:30 · Yahoo
CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo
2026-09-18 10:30 · Yahoo
CDT Highlights Sarborg’s Application of Signature Intelligence and Quantum Computing Models to Mental Health
2026-09-10 11:00 · Yahoo
CDT Provides Capital Update and Confirms No Nasdaq Deficiencies
2026-09-02 09:00 · Yahoo
CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth
2026-09-01 12:00 · Yahoo
CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio
2026-08-28 09:00 · Yahoo
CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide Market
2026-08-25 09:00 · Yahoo
CDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property Expansion
2026-08-03 12:30 · Yahoo
CDT Highlights Sarborg's Patent Filing Extending Quantum-Enabled PRISM Platform to Sugarcane
2026-07-20 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.